Related Experiment Video
Updated: Jul 20, 2026
07:21
Subcutaneous Angiotensin II Infusion using Osmotic Pumps Induces Aortic Aneurysms in Mice
Published on: September 28, 2015
Angioedema and C1 inhibitor deficiency
1Mary Imogene Bassett Hospital, Division of Allergy-Immunology, Cooperstown, New York.
Annals of Allergy
|September 1, 1992
Summary
Hereditary angioedema, caused by C1 inhibitor deficiency, leads to severe swelling and can be fatal. Improved understanding is refining diagnosis and treatment options for this rare condition.
Area of Science:
- Biochemistry
- Immunology
- Genetics
Background:
- C1 inhibitor deficiency causes hereditary angioedema (HAE), a condition with significant morbidity and mortality.
- HAE is often underdiagnosed due to its complex presentation and varied symptoms.
- Advances in understanding the pathophysiology of angioedema are crucial for improved patient outcomes.
Purpose of the Study:
- To review the current understanding of C1 inhibitor deficiency and hereditary angioedema.
- To discuss emerging theories on the pathophysiologic mechanisms underlying angioedema episodes.
- To provide an overview of evolving and newly available therapeutic interventions for HAE.
Main Methods:
- Literature review of biochemical and clinical studies on C1 inhibitor deficiency and hereditary angioedema.
- Analysis of pathophysiologic mechanisms based on current scientific understanding.
- Evaluation of existing and emerging therapeutic strategies for managing angioedema.
Main Results:
- C1 inhibitor deficiency is a primary cause of hereditary angioedema, characterized by recurrent swelling.
- Multiple pathophysiologic theories exist, highlighting the complexity of angioedema development.
- Therapeutic interventions are advancing, with new treatments showing promise.
Conclusions:
- Improved diagnostic approaches are needed for timely identification of C1 inhibitor deficiency.
- Further research into angioedema pathophysiology may lead to more targeted therapies.
- The availability of novel treatments in the US could significantly improve HAE management.
More Related Videos
Related Concept Videos
01:30Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors
Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
01:30Antihypertensive Drugs: Angiotensin II Receptor Blockers
In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
01:25Antihypertensive Drugs: Direct Renin Inhibitors
The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
01:19Cerebral Edema l: Introduction
Cerebral edema is a pathological increase in brain water content that disrupts intracranial pressure regulation and impairs neurological function. Because the cranial vault is rigid, even modest increases in tissue volume can compromise cerebral perfusion, distort neural structures, and initiate secondary injury. Cerebral edema develops through four principal mechanisms: vasogenic, cytotoxic, interstitial, and ionic.Vasogenic EdemaVasogenic edema arises from disruption of the blood–brain...
01:22Cerebral Edema ll: Pathophysiology
Vasogenic edema is a major form of cerebral edema characterized by abnormal accumulation of fluid in the brain’s extracellular space due to disruption of the blood–brain barrier (BBB). The BBB is a specialized structure composed of endothelial cells connected by tight junctions, supported by astrocytic endfeet and a basement membrane. Under normal conditions, it tightly regulates the movement of ions, proteins, and solutes between the bloodstream and brain parenchyma. When this barrier loses...
01:21Cytotoxic Edema: Pathophysiology
Cytotoxic edema is a form of cerebral edema characterized by intracellular swelling of neurons, astrocytes, and other glial cells. It develops when the mechanisms responsible for maintaining ionic gradients across the cell membrane become impaired. Under normal physiological conditions, the sodium–potassium ATPase actively transports sodium ions out of the cell and potassium ions into the cell, preserving osmotic balance and enabling electrical signaling. This pump requires a continuous supply...